CHP
PVLA

Cable Hill Partners’s Palvella Therapeutics PVLA Stock Holding History

Cable Hill Partners’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-88
Closed -$23K – 735
2019
Q1 		$23K Hold
88
– – 0.01% 354
2018
Q4 		$19K Buy
88
+13
+17% +$4.03K 0.01% 360
2018
Q3 		$30K Buy
75
+25
+50% +$10.9K 0.01% 254
2018
Q2 		$20K Buy
50
+12
+32% +$5.71K 0.01% 334
2018
Q1 		$19K Buy
38
+13
+52% +$8.05K 0.01% 360
2017
Q4 		$15K Hold
25
– – 0.01% 482
2017
Q3 		$12K Buy
+25
New +$10.7K 0.01% 534

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Cable Hill Partners's PVLA Position: Q2 2019 in Review

Cable Hill Partners sold out of Palvella Therapeutics (PVLA) in Q2 2019, closing a stake of 88 shares — an estimated $23K sold.

Cable Hill Partners first reported a position in PVLA in Q3 2017 and held it in 7 quarters. The position peaked at $30K in Q3 2018. 93 funds tracked by Wall St. Rank hold PVLA as of Q2 2019.

  • Cable Hill Partners reported no remaining Palvella Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Cable Hill Partners sold 88 Palvella Therapeutics shares in Q2 2019, an estimated $23K.
  • Cable Hill Partners first reported a position in Palvella Therapeutics in Q3 2017 and held it in 7 quarters.
  • Cable Hill Partners's Palvella Therapeutics position peaked at $30K in Q3 2018.
  • 93 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2019.

Based on Cable Hill Partners's 13F filing for Q2 2019, filed 6 Aug 2019.